Noticias de FATE_US

06/05/2026 FATE_US — Stock Titan

Director at Fate Therapeutics (NASDAQ: FATE) exercises 25,000 stock options

06/05/2026 FATE_US — MarketBeat

HC Wainwright Issues Positive Estimate for FATE Earnings

Fate Therapeutics, Inc. (NASDAQ:FATE - Informe gratuito) - HC Wainwright aumentó sus estimaciones de ganancias por acción (EPS) para el primer trimestre de 2026 para Fate Therapeutics en un informe de investigación publicado el lunes 4 de mayo. El analista de HC Wainwright, R. Burns, ahora espera que la compañía biofarmacéutica gane ($0,28) por acción.

06/05/2026 FATE_US — Newser

What Fate Therapeutics (FATE) is doing that smart investors recognize (Weakens) 2026-05-06 - Crowd Entry Points

06/05/2026 FATE_US — Stock Titan

FATE Therapeutics (NASDAQ: FATE) director exercises options, boosts direct stake

06/05/2026 FATE_US — The Legal Advocate

What Fate Therapeutics (FATE) is doing that smart investors recognize (Weakens) 2026-05-06 - Triple MA Cross

06/05/2026 FATE_US — Newser

What Fate Therapeutics (FATE) is doing that smart investors recognize (Weakens) 2026-05-06 - Leading Diagonal

05/05/2026 FATE_US — Investing.com

FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com

05/05/2026 FATE_US — Investing.com South Africa

FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com

05/05/2026 FATE_US — MarketScreener ES ← EN

Fate Therapeutics seleccionada para el programa piloto de preparación y desarrollo de química, fabricación y controles de la FDA de EE. UU. para respaldar la preparación de fabricación de FT819

Fate Therapeutics selected for U.S. FDA chemistry, manufacturing, and controls development and readiness pilot program to support manufacturing readiness of FT819

05/05/2026 FATE_US — Investing.com UK

FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com

05/05/2026 FATE_US — GlobeNewswire ES ← EN

Fate Therapeutics seleccionada para la química de la FDA de EE. UU.

El programa piloto de desarrollo y preparación (CDRP) de química, fabricación y controles (CMC) de la FDA respalda la aceleración de la preparación de fabricación para...

05/05/2026 FATE_US — Stock Titan

FDA picks Fate's lupus cell therapy for manufacturing-readiness pilot

05/05/2026 FATE_US — MarketBeat

Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday

Fate Therapeutics (NASDAQ:FATE) publicará sus resultados del primer trimestre de 2026 antes de que se abra el mercado el martes 12 de mayo. (Ver informe de resultados en https://www.marketbeat.com/earnings/reports/2026-5-12-fate-therapeutics-inc-stock/)

05/05/2026 FATE_US — Investing.com

FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com

05/05/2026 FATE_US — Yahoo Finance

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

05/05/2026 FATE_US — Investing.com

FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program

05/05/2026 FATE_US — The Manila Times

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

05/05/2026 FATE_US — GlobeNewswire

Fate Therapeutics Selected for U.S. FDA Chemistry,

05/05/2026 FATE_US — MarketScreener

Fate Therapeutics Inc Selected for FDA Chemistry Manufacturing and Controls Development and Readiness Pilot Program for FT819